Effect of Proton-Pump Inhibitors on NSAID-Induced Enteropathy

Addition of a PPI in patients using an NSAID was associated with increased incidence of small-bowel lesions but not symptoms or adverse events.

It is well established that proton-pump inhibitors (PPIs) reduce the risk for upper gastrointestinal bleeding from nonsteroidal anti-inflammatory drugs (NSAIDs), but some data suggest they may exacerbate NSAID-associated enteropathy.

Investigators in Japan performed an industry-funded, randomized, placebo-controlled study in 60 healthy volunteers. After a baseline capsule endoscopy (CE), participants were randomized to receive celecoxib (200 mg twice daily) with either rabeprazole (20 mg) or a placebo once daily for 2 weeks, after which the CE was repeated.

The incidence of small-bowel lesions was higher in the PPI group than in the placebo group (44.4% vs. 16.7%, P=0.04; relative risk, 2.67; 95% confidence interval, 1.08–6.58). The number of…

Reviewing Author

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

Effect of Proton-Pump Inhibitors on NSAID-Induced Enteropathy

Topics

Reviewing Author